Erratum to: The impact of the Oncotype Dx breast cancer assay in clinical practice: A systematic review and meta-analysis (Breast Cancer Research and Treatment (2013) 141, (13-22) DOI: 10.1007/s10549-013-2666-z);The impact of the Oncotype Dx breast cancer assay in clinical practice: A systematic review and meta-analysis

Breast Cancer Research and Treatment

Volumn 141, Issue 1, 2013, Pages 13-22

  Carlson, Josh J ^a,b   Roth, Joshua A ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Gene expression; Meta analysis

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ASSAY; BREAST CANCER; BREAST CANCER ASSAY; CANCER ADJUVANT THERAPY; EARLY CANCER; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES, FACTUAL; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PATIENT SELECTION; PROGNOSIS; PUBLICATION BIAS; RECEPTORS, ESTROGEN; RISK ASSESSMENT;

EID: 84884286307     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3009-4     Document Type: Erratum

References (55)

1. National Comprehensive Cancer Network (2012) NCCN Clinical practice guidelines in oncology: breast cancer V.1.2012
2. Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL (2005) Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med 7(6):380-389. doi: 10.109701.gim.0000170776.31248.75
3. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432-444. doi: 10.1016/s0140-6736(11) 61625-5
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717. doi: 10.1016/s0140-6736(05)66544-0
5. Griggs JJ, Hawley ST, Graff JJ, Hamilton AS, Jagsi R, Janz NK, Mujahid MS, Friese CR, Salem B, Abrahamse PH, Katz SJ (2012) Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol 30(25):3058-3064. doi: 10.1200/JCO.2012.41.9564
6. Albain KS, Paik S, van't Veer L (2009) Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18(Suppl 3):S141-S145. doi: 10.1016/S0960-9776(09) 70290-5
7. Arpino G, Generali D, Sapino A, Lucia DM, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L (2013) Gene expression profiling in breast cancer: a clinical perspective. Breast. doi: 10.1016/j.breast.2013.01.016
8. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, Goodman SN (2008) Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med 148(5):358-369
9. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726-3734. doi: 10.1200/jco.2005.04.7985
10. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98(17):1183-1192. doi: 10.1093/jnci/djj329
11. Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM (2009) Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 113(2):275-283. doi: 10.1007/s10549-008-9939-y
12. Genomic Health. Oncotype Dx-Information for patients and caregivers http://www.oncotypedx.com/en-US/Breast/PatientCaregiver/OncoOverview.aspx. Accessed 6 Jun 2012
13. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26(5):721-728. doi: 10.1200/jco.2007.15.1068
14. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28(10):1677-1683. doi: 10.1200/jco.2009.23.7610
15. Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, Geyer CE Jr, Mamounas EP, Wickerham DL, Wolmark N (2011) Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 127(1):133-142. doi: 10.1007/s10549-010-1331-z
16. ClinicalTrials.gov (2011) Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (The TAILORx Trial). http://www.clinicaltrials.gov/ct2/show/ NCT00310180?term=oncotype&rank=3. Accessed 25 Feb 2011
17. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826. doi: 10.1056/NEJMoa041588
18. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-5312. doi: 10.1200/JCO.2007.14.2364
19. Genomic Health. Corporate fact sheet. http://files.shareholder.com/ downloads/GHDX/2036901272x0x237157/FFA8A1C1-117B-411E-86A2-FFFDA42F0CFE/ FactSheet.pdf.Accessed 25 Aug 2012
20. Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11(5):313-324
21. Hornberger J, Chien R, Krebs K, Hochheiser L (2011) US Insurance Program's experience with a multigene assay for early-stage breast cancer. J Oncol Pract 7(3 Suppl):e38s-e45s. doi: 10.1200/JOP.2011.000303
22. Oakman C, Santarpia L, Di Leo A (2010) Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 7(12):725-732. doi: 10.1038/nrclinonc.2010.170
23. Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S (2011) The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 126(3):797-802. doi: 10.1007/s10549-010-1329-6
24. Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI (2008) Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196(4):527-529. doi: 10.1016/j.amjsurg.2008.06.021
25. Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, Ariad S, Delgado B, Bayme M, Koretz M (2011) The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. Ann Oncol 22(11):2381-2386. doi: 10.1093/annonc/mdq769
26. Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW (2009) The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99(6):319-323. doi: 10.1002/jso.21244
27. Hornberger J, Chien R, Krebs K, Hochheiser L (2011) US insurance program's experience with a multigene assay for early-stage breast cancer. Am J Manag Care 17(5 Spec No):e194-202
28. Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ, Acs PI, Gordan L, Acs G (2011) The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist 16(11):1520-1526. doi: 10.1634/theoncologist.2011-0045
29. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L (2010) Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22):5161-5167. doi: 10.1002/cncr.25269
30. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4):381-387. doi: 10.1111/j.1524-4733.2010.00724.x
31. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671-1676. doi: 10.1200/jco.2008.20.2119
32. Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O'Regan RM (2012) 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118(3):788-796. doi: 10.1002/cncr.26180
33. Oratz R, Paul D, Cohn AL, Sedlacek SM (2007) Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 3(4):182-186. doi: 10.1200/jop.0742001
34. Partin JF, Mamounas EP (2011) Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer. Ann Surg Oncol 18(12):3399-3406. doi: 10.1245/s10434-011-1698-z
35. Tatarian T, Damle S, McSwain AP, Ojong-Ntui M, Tabbara I, Teal CB (2011) Clinical utility and therapeutic implications of oncotype analysis in patients with breast cancer. Ann Surg Oncol 18:S182
36. Tzeng JP, Mayer D, Richman AR, Lipkus I, Han PK, Valle CG, Carey LA, Brewer NT (2010) Women's experiences with genomic testing for breast cancer recurrence risk. Cancer 116(8):1992-2000. doi: 10.1002/cncr.24990
37. Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B (2008) Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 112(4):731-736. doi: 10.1002/cncr.23225
38. Moinuddin I YS, Goodman J (2009) Effect of menopausal status and oncotype recurrence score on treatment choice for early-stage receptor-positive breast cancer. Paper presented at the American Society of Clinical Oncology Breast Cancer Symposium
39. Guth AA FS, Fei K, Franco R, Bickell N (2011) Utilization of Oncotype DX to predict chemotherapy use in an innercity population. Paper presented at the American Society of Clinical Oncology Annual Meeting
40. Goodwin MC HJ, Diego M, Frazier TG (2009) Impact of Oncotype DXTM recurrence score and tumor size on making chemotherapy decisions in breast cancer patients. Paper presented at the Sand Antonio Breast Cancer Symposium
41. Gregg X BT, Rowley B, Rees W (2009) Experience with use of the Oncotype DX gene assay test in a multicenter community-based healthcare system. Paper presented at the San Antonio Breast Cancer Symposium
42. de Boer RH BC, Speakman D, Mann B (2011) Australian decision impact study: the impact of Oncotype DX recurrence score (RS) on adjuvant treatment decisions in hormone receptor positive (HR+), node negative (N0) and node positive (N+) early stage breast cancer (ESBC) in the multidisciplinary clinic (MDC). Paper presented at the San Antonio Breast Cancer Symposium
43. Holt S BG, Brinkworth E, Durrani S, Jones S, Khawaja S, Laggner U, Moe M, Pudney D, Pitcher S, Rolles M, Sharaiha Y, Whelan S (2011) Results from a prospective clinical study on the impact of Oncotype DX on adjuvant treatment decision making in a cohort of 142 UK patients. Paper presented at the San Antonio Breast Cancer Symposium
44. Rezai M EW, Kummel S, Kuhn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, Jackisch C, Witzel I, Eidtmann H, Kaufmann M, Blohmer JU (2011) Impact of the recurrence score on adjuvant decision-making in ER-positive early breast cancer - results of a large prospective multicentre decision impact study in node negative and node positive disease. Paper presented at the San Antonio Breast Cancer Symposium
45. Patel H HK, Kaplan C, Davidson R, DeMichele A, Fox KR, Domcheck SM (2007) Utilization of Oncotype DX in node-negative, ER-positive breast cancer patients. Paper presented at the American Society of Clinical Oncology Annual Meeting
46. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264-269, W264
47. Turaga K, Acs G, Laronga C (2010) Gene expression profiling in breast cancer. Cancer Control 17(3):177-182
48. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455-463
49. Greenland S (1994) Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 140(3):290-296
50. Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282(11):1054-1060
51. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2009) Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 11(1):66-73. doi: 10.1097/GIM.0b013e3181928f56
52. Marchionni L, Wilson RF, Marinopoulos SS, Wolff AC, Parmigiani G, Bass EB, Goodman SN (2007) Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep Technol Assess (Full Rep) 160:1-105
53. Dunn L, Demichele A (2009) Genomic predictors of outcome and treatment response in breast cancer. Mol Diagn Ther 13(2):73-90. doi: 10.2165/01250444- 200913020-00002
54. Kratz JR, He J, Van Den Eeden SK, Zhu Z-H, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang M-C, Yeh C-C, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379(9818):823-832. doi: 10.1016/s0140-6736(11)61941-7
55. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, Beaumont C, Clark-Langone KM, Yoshizawa CN, Lee M, Watson D, Shak S, Kerr DJ (2011) Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29(35):4611-4619. doi: 10.1200/jco.2010.32.8732